As a result of these pivotal findings, the Food and Drug Administration authorized the use of PD-L1 inhibitors, such as durvalumab and atezolizumab, in conjunction with chemotherapy as the primary treatment regimen for previously untreated patients with ES-SCLC in 2019 and 2020, respectively. The gene discussed is CD274; the disease is small cell lung carcinoma.